The second mega-merger in as many quarters means a huge M&A year is in the making, but a look at deal volume tells another story.
Indulging in M&A is not the way to bump up share prices as oncology-focused companies prove to be the sector’s darlings.
Abbvie’s bid for Allergan shows that the Botox franchise is impenetrable. The market agrees.
2019’s second mega-merger has emerged, and Vantage has crunched some EvaluatePharma data to help dissect the proposed deal.
Abbvie’s swoop on Allergan looks like a case of opportunism over innovation.
The developer of Keytruda is starting to look like a one-drug company; what must it do to avoid becoming the next Abbvie?
On sales per employee Abbvie and Bristol-Myers Squibb lead the big pharma pack, while Sanofi and Astrazeneca are the sector laggards.
Pfizer’s Array buyout ranks as 2019’s second largest, but the price sits in a lonely space in the deal universe.